HomeAI · summaries
Storia in 2 fonti
ASCO26: Blood cancer readouts take centre stage - Pharmaceutical Technology
Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
pharmaceutical-technology.com
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
- ·
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.
